TD Cowen analyst Josh Jennings has reiterated their bullish stance on CBLL stock, giving a Buy rating on April 11.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Josh Jennings has given his Buy rating due to a combination of factors that highlight Ceribell, Inc.’s promising commercial trajectory. The company’s technology is proving effective in both clinical and economic terms, which is enhancing its appeal to hospitals across the United States. This positive feedback from healthcare professionals strengthens the belief in Ceribell’s market potential.
Furthermore, Ceribell’s impressive revenue growth since its IPO in October 2024 underscores its capability to perform among the top-tier companies in the MedTech sector. With a strong revenue growth of 48% in the third quarter followed by 41% in the fourth quarter of 2024, the company is on a solid path. Management’s revenue guidance for 2025, coupled with strategic expansion plans, including increasing territory managers, suggests a sustainable growth outlook, reinforcing the Buy recommendation.